Adam Townsend - Oct 3, 2022 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role
Chief Commercial Officer
Signature
/s/ David Watson, attorney-in-fact for Adam Townsend
Stock symbol
APLS
Transactions as of
Oct 3, 2022
Transactions value $
-$258,000
Form type
4
Date filed
10/5/2022, 05:12 PM
Previous filing
Sep 7, 2022
Next filing
Nov 7, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Options Exercise $75.5K +5K +11.65% $15.09 47.9K Oct 3, 2022 Direct F1
transaction APLS Common Stock Sale -$333K -5K -10.44% $66.69 42.9K Oct 3, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APLS Stock Option (Right to Buy) Options Exercise $0 -5K -1.55% $0.00 318K Oct 3, 2022 Common Stock 5K $15.09 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This is a scheduled exercise and sale form an established 10b5-1 plan.
F2 This represents a stock option granted 11/16/2018 that vest as to 25% of the shares underlying the options on the first anniversary of the grant, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to continued service.